Shum B, Duffull S B, Taylor P J, Tett S E
School of Pharmacy, University of Queensland, Brisbane, Australia.
Br J Clin Pharmacol. 2003 Aug;56(2):188-97. doi: 10.1046/j.1365-2125.2003.01863.x.
To develop a population pharmacokinetic model for mycophenolic acid in adult kidney transplant recipients, quantifying average population pharmacokinetic parameter values, and between- and within-subject variability and to evaluate the influence of covariates on the pharmacokinetic variability.
Pharmacokinetic data for mycophenolic acid and covariate information were previously available from 22 patients who underwent kidney transplantation at the Princess Alexandra Hospital. All patients received mycophenolate mofetil 1 g orally twice daily. A total of 557 concentration-time points were available. Data were analysed using the first-order method in NONMEM (version 5 level 1.1) using the G77 FORTRAN compiler.
The best base model was a two-compartment model with a lag time (apparent oral clearance was 27 l h(-1), and apparent volume of the central compartment 98 l). There was visual evidence of complex absorption and time-dependent clearance processes, but they could not be successfully modelled in this study. Weight was investigated as a covariate, but no significant relationship was determined.
The complexity in determining the pharmacokinetics of mycophenolic acid is currently underestimated. More complex pharmacokinetic models, though not supported by the limited data collected for this study, may prove useful in the future. The large between-subject and between-occasion variability and the possibility of nonlinear processes associated with the pharmacokinetics of mycophenolic acid raise questions about the value of the use of therapeutic monitoring and limited sampling strategies.
建立成年肾移植受者霉酚酸的群体药代动力学模型,量化群体药代动力学参数的平均数值、个体间和个体内变异性,并评估协变量对药代动力学变异性的影响。
先前已获得亚历山德拉公主医院22例接受肾移植患者的霉酚酸药代动力学数据和协变量信息。所有患者均口服霉酚酸酯,每日2次,每次1 g。共获得557个浓度-时间点。使用G77 FORTRAN编译器,采用NONMEM(版本5 1.1级)中的一级方法对数据进行分析。
最佳基础模型为具有滞后时间的二室模型(表观口服清除率为27 l·h-1,中央室表观容积为98 l)。有直观证据表明存在复杂的吸收和时间依赖性清除过程,但在本研究中无法成功建模。研究了体重作为协变量,但未确定显著关系。
目前对霉酚酸药代动力学测定的复杂性估计不足。更复杂的药代动力学模型虽然未得到本研究收集的有限数据的支持,但未来可能会证明有用。霉酚酸药代动力学相关的个体间和个体内较大变异性以及非线性过程的可能性,引发了关于治疗药物监测和有限采样策略价值的疑问。